Humanized Anti-TAG 72 CC49 for Diagnosis and Therapy of Human Carcinomas

Feb. 1, 2012

Humanized Anti-TAG 72 CC49 for Diagnosis and Therapy of Human Carcinomas

Technology description

Summary

Tumor associated glycoprotein (TAG-72) is expressed on the cells of a majority of human carcinomas, including colorectal, gastric, pancreatic, breast, lung, and ovarian. The murine monoclonal antibody (mAb) CC49 specifically recognizes TAG-72 and has a higher affinity for TAG-72 than its predecessor, B72.3.

The present invention discloses new humanized variants of CC49 that have a higher binding affinity to TAG-72 than previous humanized variants. Identified as HuCC49V15 and HuCC49V14, these variants also retain low immunogenicity of variable regions using sera of patients vaccinated with murine CC49.

These variants have potential benefits for use in the detection and/or treatment of a range of human carcinomas. Certain fields of use may not be available. Please contact OTT for information regarding the availability of specific fields of use.

由于技术保密工作限制，技术信息无法完全展现，请通过邮箱或短信联系我们，获取更多技术资料。